Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Long-Term Investments (2021 - 2024)

Pulmonx (LUNG) has disclosed Long-Term Investments for 4 consecutive years, with $4.3 million as the latest value for Q1 2024.

  • On a quarterly basis, Long-Term Investments rose 62.8% to $4.3 million in Q1 2024 year-over-year; TTM through Mar 2024 was $4.3 million, a 62.8% increase, with the full-year FY2023 number at $14.4 million, up 142.91% from a year prior.
  • Long-Term Investments was $4.3 million for Q1 2024 at Pulmonx, down from $14.4 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $23.3 million in Q3 2023 to a low of $2.0 million in Q2 2021.
  • A 4-year average of $7.7 million and a median of $5.3 million in 2022 define the central range for Long-Term Investments.
  • Biggest YoY gain for Long-Term Investments was 165.88% in 2023; the steepest drop was 58.66% in 2023.
  • Pulmonx's Long-Term Investments stood at $10.9 million in 2021, then plummeted by 45.86% to $5.9 million in 2022, then surged by 142.91% to $14.4 million in 2023, then tumbled by 70.17% to $4.3 million in 2024.
  • Per Business Quant, the three most recent readings for LUNG's Long-Term Investments are $4.3 million (Q1 2024), $14.4 million (Q4 2023), and $23.3 million (Q3 2023).